NVAX Novavax Inc.

4.35
-0.2  -4%
Previous Close 4.55
Open 4.62
Price To Book -0.69
Market Cap 115,611,834
Shares 26,577,433
Volume 1,326,518
Short Ratio
Av. Daily Volume 709,103
Stock charts supplied by TradingView

NewsSee all news

  1. Novavax Reports Third Quarter 2019 Financial Results

    NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., Nov. 07, 2019 (GLOBE

  2. Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019

    GAITHERSBURG, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report

  3. Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults

    First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu Top-line clinical data expected in the first quarter of 2020 Phase 3 results expected to support a future BLA and licensure of NanoFlu using the

  4. Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    GAITHERSBURG, Md., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C.

  5. Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    GAITHERSBURG, Md., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data due 1Q 2020.
NanoFlu vaccine
Influenza
Phase 2 safety and immunogenicity data released July 24, 2017 - efficacy trial to be initiated 2018.
RSV F Vaccine immunogenicity trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 released September 15, 2016 did not demonstrate efficacy.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 2 data released September 15, 2016.
RSV F Vaccine rollover trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 top-line data released March 28, 2019 - primary endpoint not met. Noted June 10, 2019 that a further Phase 3 trial is required.
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Further Phase 2 trials planned
Seasonal Influenza Vaccine
Seasonal Flu

Latest News

  1. Novavax Reports Third Quarter 2019 Financial Results

    NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., Nov. 07, 2019 (GLOBE

  2. Novavax to Host Conference Call to Discuss Third Quarter Financial Results on November 7, 2019

    GAITHERSBURG, Md., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report

  3. Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults

    First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu Top-line clinical data expected in the first quarter of 2020 Phase 3 results expected to support a future BLA and licensure of NanoFlu using the

  4. Novavax to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    GAITHERSBURG, Md., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C.

  5. Novavax to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    GAITHERSBURG, Md., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C.